兰峰，1982年生，籍贯福建，从事心血管病学基础和转化研究，研究员，博士生导师。2000年考入中央民族大学生物科学专业，2004年获得学士学位。2004-2009年在北京大学细胞生物学专业攻读博士学位，从事多能干细胞生物学研究。2009-2014于斯坦福大学心血管研究所进行博士后研究工作。2014-2019进入首都医科大学附属北京安贞医院，任教授，博导，并独立带领课题组开展遗传性心脏病研究。2020年进入阜外医院，2021年升为助理研究员。

采用最前沿的多能干细胞模型（hPSC）和碱基编辑技术，研究遗传性心脏病（心肌病、心律失常）的发病机制，建立一系列精准诊断和治疗的新方法，并进行临床应用转化。建立了首个肥厚型心肌病iPS模型。带领团队首次采用碱基编辑器对肥厚型心肌病模型进行在体基因编辑治疗。

1. Jiang Y#, Li X#, Guo T#, Lu WJ, Ma S, Chang Y, Song Y, Zhang S, Bai R, Wang H, Qi M, Jiang H*, Zhang H*, Lan F*. Ranolazine rescues the heart failure phenotype of PLN-deficient human pluripotent stem cell-derived cardiomyocytes. Stem Cell Reports. 2022 Apr 12;17(4):804-819. (IF= 7.2935)

2. Ma S#, Jiang W#, Liu X#, Lu W, Qi t, Wei J, Wu F, Chang Y, Zhang S, Song Y, Rui Bai R, Wang J, Lee A, Zhang H*, Wang Y*, Lan F*. Efficient correction of a hypertrophic cardiomyopathy mutation by ABEmax-NG. Circulation Research, 2021, Oct 29;129(10):895-908. (IF= 23.2125)

3. Guo R, Wan F, Xu Q, Feng T, Yang H, Gong Y, Ma S, Chang Y, Zhang S, Jiang Y, Wang H, Chang D, Zhang H, Ling Y*, Lan F*. Cell sheet formation enhances the therapeutic effects of human umbilical cord mesenchymal stem cells on myocardial infarction as a bioactive material. Bioactive Material, 2021, Mar 5;6(9):2999-3012. (IF= 16.8737)

4. Gao Y, Wu S, Pan J, Zhang K, Li X, Xu Y, Jin C, He X, Shi J, Ma L, Wu F, Yao Y, Wang P, He Q, Lan F*, Zhang H*, Tian M*. CRISPR/Cas9-edited triple-fusion reporter gene imaging of dynamics and function of transplanted human urinary-induced pluripotent stem cell-derived cardiomyocytes. Eur J Nucl Med Mol Imaging. 2021 Mar;48(3):708-720. (IF= 10.0567)

5. Wang D, Zhang C, Wang B, Li B, Wang Q, Liu D, Wang H, Zhou Y, Shi L, Lan F*, Wang Y*. Optimized CRISPR guide RNA design for two high-fidelity Cas9 variants by deep learning. Nature Communication. 2019 Sep 19;10(1):4284. (IF= 17.6939)

6. Li X, Lu W, Li Y, Wu F, Bai R, Ma S, Dong T, Zhong H, Lee A, Wang Y*, Lan F*. MLP-deficient human pluripotent stem cell derived cardiomyocytes develop hypertrophic cardiomyopathy and heart failure phenotypes due to abnormal calcium handling. Cell Death Disease. 2019 Aug 13;10(8):610. (IF= 9.6854)

7. Ke B, Zeng Y, Zhao Z, Han F, Liu T, Wang J, Khalique A, Lu WJ, Chong J, Lan F*, He H*. Uric acid: a potent molecular contributor to pluripotent stem cell cardiac differentiation via mesoderm specification. Cell Death and Differentiation. 2019 May;26(5):826-842. (IF= 12.0673)

8. Jiang Q, Li K, Lu WJ, Li S, Chen X, Liu XJ, Yuan J, Ding Q, Lan F*, Cai SQ*. Identification of small-molecule ion channel modulators in C. elegans channelopathy models. Nature Communication. 2018 Sep 26;9(1):3941 (IF= 17.6939)

9. Lan F#,Lee AS#, Liang P#, Sanchez-Freire V, Nguyen PK, Wang L, Han L, Yen M, Wang Y, Sun N, Abilez OJ, Navarrete EG, Wheeler M, Lewis R, Yamaguchi Y, Ashley EA, Bers DM, Robbins RC, Longaker MT, Wu JC. Abnormal Calcium Handling Properties Underlie Familial Hypertrophic Cardiomyopathy Pathology in Patient-Specific Induced Pluripotent Stem Cells. Cell Stem Cell. 2013;12:101-113. (IF= 25.2698，F1000)

10. Lan F#, Liu J#, Narsinh KH, Hu S, Han L, Lee AS, Karow M, Nguyen PK, Nag D, Calos MP, Robbins RC, Wu JC*. Safe genetic modification of cardiac stem cells using a site-specific integration technique. Circulation. 2012;126:S20-28 (IF= 39.9175)